Roche: drug gets Breakthrough stratus for Alzheimer's diseas

(CercleFinance.com) - On Friday Roche announced that gantenerumab, an antibody for subcutaneous administration, has been granted "Breakthrough Therapy" designation by the US FDA for the treatment of Alzheimer's disease.


This designation is based on data showing that gantenerumab significantly reduced cerebral amyloid plaque, a pathological feature of AD, in several trials and studies.

Pivotal trials have been evaluating gantenerumab in over 2,000 participants for over two years. These trials are expected to be completed in the second half of 2022.


Copyright (c) 2021 CercleFinance.com. All rights reserved.